期刊文献+

羟苯磺酸钙对5/6肾切除大鼠肾脏微血管的保护机制 被引量:2

Effects of Calcium dobesilate on renal microvasculature injury in 5/6 subtotal nephrectomy rats model
下载PDF
导出
摘要 目的探讨羟苯磺酸钙对5/6肾切除大鼠肾脏微血管的保护作用及其机制。方法复制5/6肾切除大鼠模型,设5/6肾切除模型组和羟苯磺酸钙干预组,在二次手术后第1、2、4、8、12周观察各组大鼠肾功能及残肾组织病理改变。采用免疫组化观察肾脏Ang-1和CD31表达的变化,RT-PCR观察肾脏Ang-1 mRNA的表达并行相关性分析。结果与同时点模型组比较,羟苯磺酸钙干预组大鼠尿蛋白减少、肾功能改善、残肾组织病理改变明显减轻。自第2周开始Ang-1 mRNA及蛋白表达水平升高,其后期的下调趋势变缓、CD31表达增强、肾脏微血管病变显著改善。结论羟苯磺酸钙可能通过增强Ang-1早期的上调幅度并延缓后期的下调来改善5/6。肾切除大鼠肾脏的微血管病变,从而保护肾脏。 Objective To observe and probe into the effects and mechanism of action of calcium dobesilate on the renal mierovasculature injury in the remnant kidneys of rats with 5/6 nephrectomy. Methods Rat model were established in adult male SD rats by 5/6 nephrectomy. The rats were randomly divided into model and calcium dobesilate intervention group. The renal function and histopathological changes were evaluated at 1, 2, 4, 8 and 12 weeks after operation finished. The expressions of Ang-1 and CD31 in renal were detected by immunohistochemistry. Ang-1 mRNA was detected by RT-PCR at the same time-points. The levels of Ang-1 and CD31 were quantified by computer image analysis. Results In calcium dobesilate intervention group, urine protein decreased,the renal function improved and the pathological changes of remnant kidney lessen significantly as compared with the model group at the same time-points. Except at 1 w, the expression of Ang-1 and CD31 in the intervention group was higher than that in the subtotal nephrectomy group at the other time points, and the difference between the groups was significant (P〈0. 05, P〈0. 01 ). Conclusions Calcium dobesilate may protect kidney by increasing the content of angiopoietin-1 to improve the renal microvasculature injury in the remnant kidney.
作者 刘兰香 杨晓
出处 《临床肾脏病杂志》 2008年第7期320-323,F0003,共5页 Journal Of Clinical Nephrology
关键词 羟苯磺酸钙 5/6肾切除 促血管生成素-1 微血管病变 Calcium dobesilate 5/6 nephrectomy Angiopoietin-1 Microvasculature injury
  • 相关文献

参考文献8

  • 1Negri AL. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents. J Nephrol, 2004, 17 :496-503.
  • 2Uchimura H, Marumo T, Takase O, et al. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol, 2005, 16:997-1004.
  • 3Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol, 2002, 160: 1683-1693.
  • 4Won Kim, Sang-Ok Moon, Sang Yong Lee, et al. COMP-Angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol, 2006, 17:2474-2483.
  • 5Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cell in promoting angiogenesis. Cell, 2000, 102: 199-209.
  • 6Pizurki L, Zhou Z, Glynos K, et al. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 produc tion. Br J Pharmacol, 2003, 139:329-336.
  • 7Satchell SC, Anderson KL, Mathieson PW. Angiopoietin-1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol, 2004, 15:566-574.
  • 8Kim I, Kim HG, So JN, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3-kinase/akt signal transduction pathway. Circ Res, 2000, 86: 24-29.

同被引文献44

引证文献2

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部